Bronchiectasis (BE)

BE: a risk factor for NTM that is underpinned by inflammation

A recent meta-analysis indicated that patients with BE were more than 20 times more likely to contract NTM-pulmonary disease (NTM-PD) than the general population.[1]

Once NTM infection is established many patients experience significant deterioration in lung health, quality of life and life expectancy.[2,3] Inflammation, impaired mucociliary clearance and infection form a self-perpetuating vicious vortex in BE [4] which results in a perfect breeding ground in the lung for infection with NTM.[5]

Persistent inflammation damages the lung’s structural integrity, facilitates chronic infection and impairs mucociliary clearance.[4] These actions further upregulate inflammation leading to a self-perpetuating cycle of damage.[4] 

Key resources on the role of inflammation in BE

BE: Webinar "Individualizing bronchiectasis therapy - let's challenge current thinking"

Video

BE: Webinar "Individualizing bronchiectasis therapy - let's challenge current thinking"

Duration: 60 mins

Professor James Chalmers, Professor Stefano Aliberti, Dr Eva Polverino

Recording of webinar "Individualizing bronchiectasis therapy - let's challenge current thinking" that took place on the 2nd of November 2023.

BE: ERS 2023 symposium: Dr Jekyll and Mr Hyde: the two faces of bronchiectasis

Video

BE: ERS 2023 symposium: Dr Jekyll and Mr Hyde: the two faces of bronchiectasis

Duration: 84 mins

Professor Tobias Welte, Dr Anne O'Donnell, Dr Charles Haworth, Dr Eva Polverino and Dr Pieter Goeminne

Recording of symposium "Dr Jekyll and Mr Hyde: the two faces of bronchiectasis" that took place on 10th September at ERS 2023.

BE: The role of neutrophilic inflammation in bronchiectasis

Video

BE: The role of neutrophilic inflammation in bronchiectasis

Duration: 50 mins

Professor James D Chalmers

Lecture given during WBNC 2022 conference in Prague exploring the role of inflammation in bronchiectasis

BE: The role of inflammation in the vicious vortex of bronchiectasis - Is it time to re-evaluate?

Video

BE: The role of inflammation in the vicious vortex of bronchiectasis - Is it time to re-evaluate?

Duration: 54 mins

Professor Stefano Aliberti

Recording of webinar on the role of Inflammation in the vicious vortex of Bronchiectasis with Prof. Stefano Aliberti, Dr Holly Keir and Dr Pieter Goeminne that took place on 8th of June 2023

BE: Webinar "Addressing the vortex of inflammation in non-CF bronchiectasis"

Video

BE: Webinar "Addressing the vortex of inflammation in non-CF bronchiectasis"

Duration: 66 mins

Professor Stuart Elborn

Recording of webinar "Addressing the vortex of inflammation in non-CF bronchiectasis" with Prof. Stuart Elbon, Prof. Catherine Greene, Prof. James Chalmersthat that took place on 24th May 2022.

BE is characterised by exacerbations caused by neutrophilic inflammation; the levels of neutrophilic inflammation correlate with exacerbation frequency, lung damage and BE severity. [6,7]

The pathogenesis of bronchiectasis

The vicious vortex, adapted from Flume et al. [5]

Consider and treat bronchiectasis, being aware of the role of inflammation.[8]

References

  1. Loebinger MR, et al. Chest 2023 (in press)
  2. Kwak N, et al. BMC Pulm Med 2020;20:293
  3. Marras TK, et al. Emerg Infect Dis 2017;23:468–76
  4. Adjemian J, et al. Am J Respir Crit Care Med 2012;185:881–6.
  5. Flume PA, et al. Lancet 2018;392:880-90.
  6. Chalmers JD, et al. Am J Respir Crit Care Med, 2017;195:1384-1393
  7. Keir HR, et al. Lancet Respir Med, 2021;9:873-884
  8. Keir HR, et al. Semin Respir Crit Care Med 2021;42:499–512.

 

Job code: MED-EU7-00099  Date: August 2023

Professor Stefano Aliberti

Chief of Respiratory Unit

Italy

Professor Stefano Aliberti

Stefano Aliberti is Chief of Respiratory Unit at Humanitas Research Hospital, Milan, Italy.

He specialises in respiratory infectious diseases, including bronchiectasis and pneumonia.

He is Founder and Co-chair of The European Bronchiectasis Registry (EMBARC) and Work Package Leader of the European Respiratory Society (ERS) Clinical Research Collaboration (EMBARC 2) for Clinical Trials Support and Feasibility.

He is Director of the Italian Registry of Adults with non-cystic fibrosis bronchiectasis (IRIDE), the Italian Registry on Pulmonary Non-tuberculous Mycobacteria (IRENE) and Director of the bronchiectasis and NTM Program at the Policlinico University Hospital in Milan, Italy.

Stefano Aliberti is also Chair of the ERS END-COVID Clinical Research Collaboration and Associate Editor (chest infections) for Chest.

Thank you for registering your interest

Sorry, an error has occurred: